NTRK1 and neoplasm: We believed that the combination of vincristine and toceranib increases the antitumor activity because toceranib inhibits both normal and mutated tyrosine kinase receptors that are needed for phosphorylation and downstream signaling, kills tumor cells, and decreases the blood supply to the tumor because of its antiangiogenic effect (16).